
Opinion|Videos|October 14, 2024
Key Findings From ARANOTE: Darolutamide Plus ADT in mHSPC
Author(s)Fred Saad, CQ, MD, FRCS, FCAHS
Key Takeaways
- Darolutamide addition to ADT significantly improved progression-free survival in metastatic hormone-sensitive prostate cancer patients compared to placebo.
- The trial highlighted darolutamide's favorable safety profile, supporting its use in combination with ADT.
The panelist discusses how the ARANOTE trial demonstrated significant benefits of adding darolutamide to androgen deprivation therapy for patients with metastatic hormone-sensitive prostate cancer, showing improvements in radiographic progression-free survival and other key outcomes.
Advertisement
Video Content above is prompted by the following:
- Discuss the findings of the ARANOTE trial (NCT04736199), which compared the addition of darolutamide or placebo to androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures
2
Apalutamide is linked to fewer CNS-related conditions in patients with nmCRPC
3
Prostate MRI is linked with higher sensitivity, NPV vs micro-ultrasound in pilot study
4
Michael Cookson, MD, discusses new strategies for treatment intensification in prostate cancer
5




















